A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study will determine if MK-3614, given as single doses, is safe and well tolerated in healthy males and male participants with mild to moderate hypertension.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Healthy participants between 18 to 45 years of age; otherwise healthy participants between 18 to 55 years of age newly diagnosed with grade 1 or 2 hypertension

• Participant is in good general health

• Participant is a nonsmoker

Exclusion Criteria:

• Participant has a history of stroke, seizure or major neurological disease

• Participant has functional disability that can interfere with rising from a sitting position to a standing position

• Participant has a family history of a bleeding or clotting disorder

• Participant has a history of cancer

• Participant is unable to refrain from or anticipates the use of any prescription or non-prescription medication during the study

• Participant consumes excessive amounts of alcohol or caffeine

• Participant has had major surgery, donated blood or participated in another investigational study in the past 4 weeks.